BR112017005299A2 - inibidores de lrrk2 cinase macrocíclicos - Google Patents
inibidores de lrrk2 cinase macrocíclicosInfo
- Publication number
- BR112017005299A2 BR112017005299A2 BR112017005299A BR112017005299A BR112017005299A2 BR 112017005299 A2 BR112017005299 A2 BR 112017005299A2 BR 112017005299 A BR112017005299 A BR 112017005299A BR 112017005299 A BR112017005299 A BR 112017005299A BR 112017005299 A2 BR112017005299 A2 BR 112017005299A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- kinase
- disease
- compounds
- lrrk2 kinase
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 abstract 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290279 | 2014-09-17 | ||
| PCT/EP2015/071349 WO2016042089A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic lrrk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017005299A2 true BR112017005299A2 (pt) | 2017-12-12 |
Family
ID=51752058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017005299A BR112017005299A2 (pt) | 2014-09-17 | 2015-09-17 | inibidores de lrrk2 cinase macrocíclicos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10377772B2 (enExample) |
| EP (1) | EP3194405B1 (enExample) |
| JP (1) | JP2017529365A (enExample) |
| KR (1) | KR20170048599A (enExample) |
| CN (1) | CN107108641A (enExample) |
| AU (1) | AU2015316801B2 (enExample) |
| BR (1) | BR112017005299A2 (enExample) |
| CA (1) | CA2960777A1 (enExample) |
| DK (1) | DK3194405T3 (enExample) |
| EA (1) | EA032838B1 (enExample) |
| ES (1) | ES2717510T3 (enExample) |
| HU (1) | HUE043972T2 (enExample) |
| IL (1) | IL251054B (enExample) |
| MX (1) | MX2017003470A (enExample) |
| PL (1) | PL3194405T3 (enExample) |
| SG (1) | SG11201701936WA (enExample) |
| TR (1) | TR201904514T4 (enExample) |
| TW (1) | TW201625639A (enExample) |
| WO (1) | WO2016042089A1 (enExample) |
| ZA (1) | ZA201701841B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111221514B (zh) * | 2020-01-13 | 2023-03-03 | 陕西心像信息科技有限公司 | 基于OsgEarth的三维可视化组件实现方法及系统 |
| UY39061A (es) * | 2020-01-31 | 2022-01-31 | Oncodesign Sa | Inhibidores macrocíclicos de rip2-cinasa |
| CA3182162A1 (en) | 2020-05-06 | 2021-11-11 | Les Laboratoires Servier | New macrocyclic lrrk2 kinase inhibitors |
| TW202304935A (zh) | 2021-03-18 | 2023-02-01 | 法商施維雅藥廠 | 新穎的巨環lrrk2激酶抑制劑 |
| US20240417378A1 (en) * | 2021-10-11 | 2024-12-19 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
| AR127470A1 (es) * | 2021-10-27 | 2024-01-31 | H Lundbeck As | Inhibidores de lrrk2 |
| WO2023222005A1 (zh) * | 2022-05-18 | 2023-11-23 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
| US11958865B1 (en) | 2022-09-15 | 2024-04-16 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (LRRK2) inhibitors |
| AR132488A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| AR132486A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
| WO2024218296A1 (en) * | 2023-04-20 | 2024-10-24 | H. Lundbeck A/S | Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors |
| AR132487A1 (es) * | 2023-04-20 | 2025-07-02 | H Lundbeck As | Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| SG48049A1 (en) | 1993-10-01 | 1998-04-17 | Astra Ab | Process i |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| EA006626B1 (ru) | 1996-07-24 | 2006-02-24 | Дюпон Фармасьютикалз Компани | Азолопиримидины, фармацевтическая композиция и способ лечения |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| JP3528968B2 (ja) | 2000-12-28 | 2004-05-24 | 小野薬品工業株式会社 | 三環式複素環誘導体化合物およびその化合物を有効成分とする医薬 |
| CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| EP2316927B1 (en) | 2004-10-21 | 2014-11-05 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
| FI123725B (fi) | 2005-08-01 | 2013-10-15 | Reijo Viljanen | Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet |
| PH12012501003B1 (en) | 2005-11-16 | 2018-04-06 | Cti Biopharma Corp | Oxygen linked pyrimidine derivatives |
| WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| WO2011038572A1 (en) | 2009-09-29 | 2011-04-07 | Glaxo Group Limited | Novel compounds |
| HUE044025T2 (hu) * | 2010-05-20 | 2019-09-30 | Array Biopharma Inc | Makrociklusos vegyületek mint TRK-kináz inhibitorok |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| UA113186C2 (xx) * | 2011-09-30 | 2016-12-26 | Макроциклічні інгібітори lrrk2 кінази | |
| EA025881B1 (ru) * | 2011-09-30 | 2017-02-28 | Онкодизайн С.А. | Макроциклические ингибиторы flt3-киназы |
-
2015
- 2015-09-17 DK DK15766801.3T patent/DK3194405T3/en active
- 2015-09-17 SG SG11201701936WA patent/SG11201701936WA/en unknown
- 2015-09-17 PL PL15766801T patent/PL3194405T3/pl unknown
- 2015-09-17 TR TR2019/04514T patent/TR201904514T4/tr unknown
- 2015-09-17 AU AU2015316801A patent/AU2015316801B2/en not_active Ceased
- 2015-09-17 US US15/511,879 patent/US10377772B2/en not_active Expired - Fee Related
- 2015-09-17 JP JP2017515823A patent/JP2017529365A/ja active Pending
- 2015-09-17 TW TW104130753A patent/TW201625639A/zh unknown
- 2015-09-17 CA CA2960777A patent/CA2960777A1/en not_active Abandoned
- 2015-09-17 EP EP15766801.3A patent/EP3194405B1/en not_active Not-in-force
- 2015-09-17 CN CN201580061216.1A patent/CN107108641A/zh active Pending
- 2015-09-17 WO PCT/EP2015/071349 patent/WO2016042089A1/en not_active Ceased
- 2015-09-17 BR BR112017005299A patent/BR112017005299A2/pt not_active IP Right Cessation
- 2015-09-17 KR KR1020177010322A patent/KR20170048599A/ko not_active Withdrawn
- 2015-09-17 HU HUE15766801A patent/HUE043972T2/hu unknown
- 2015-09-17 MX MX2017003470A patent/MX2017003470A/es unknown
- 2015-09-17 EA EA201790626A patent/EA032838B1/ru not_active IP Right Cessation
- 2015-09-17 ES ES15766801T patent/ES2717510T3/es active Active
-
2017
- 2017-03-09 IL IL251054A patent/IL251054B/en not_active IP Right Cessation
- 2017-03-15 ZA ZA2017/01841A patent/ZA201701841B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR201904514T4 (tr) | 2019-04-22 |
| CA2960777A1 (en) | 2016-03-24 |
| DK3194405T3 (en) | 2019-04-15 |
| IL251054B (en) | 2019-03-31 |
| EP3194405B1 (en) | 2018-12-26 |
| AU2015316801A1 (en) | 2017-04-27 |
| ZA201701841B (en) | 2019-08-28 |
| ES2717510T3 (es) | 2019-06-21 |
| IL251054A0 (en) | 2017-04-30 |
| HUE043972T2 (hu) | 2019-09-30 |
| EP3194405A1 (en) | 2017-07-26 |
| EA032838B1 (ru) | 2019-07-31 |
| EA201790626A1 (ru) | 2017-07-31 |
| MX2017003470A (es) | 2017-08-07 |
| SG11201701936WA (en) | 2017-04-27 |
| WO2016042089A1 (en) | 2016-03-24 |
| PL3194405T4 (pl) | 2019-07-31 |
| PL3194405T3 (pl) | 2019-07-31 |
| US20170240565A1 (en) | 2017-08-24 |
| JP2017529365A (ja) | 2017-10-05 |
| KR20170048599A (ko) | 2017-05-08 |
| AU2015316801B2 (en) | 2019-03-07 |
| CN107108641A (zh) | 2017-08-29 |
| US10377772B2 (en) | 2019-08-13 |
| TW201625639A (zh) | 2016-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017005299A2 (pt) | inibidores de lrrk2 cinase macrocíclicos | |
| BR112014007654A8 (pt) | Inibidores de lrrk2 quinase macrocíclicos. | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
| BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| PH12016501307B1 (en) | Compounds | |
| BR112014022000A2 (pt) | compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| BR112015022041A2 (pt) | derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas | |
| BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| BR112016007329A2 (pt) | composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1 | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112017004035A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
| BR112018004347A2 (pt) | derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida | |
| BR112017003881A2 (pt) | derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak | |
| BR112015017678A2 (pt) | novos derivados de pirimidina como inibidores de fosfodiesterase 10 (pde-10) | |
| EA201790795A1 (ru) | СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| UY33584A (es) | Nuevos compuestos benzamida de inhibidores lrrk2 | |
| BR112016008060A8 (pt) | composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ONCODESIGN S.A. (FR) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |